Discovering Factors in the Clinical Trial Journey of Dementia Patients
NCT05850000 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-05-09
Summary
This research aims to collect comprehensive data on the clinical trial experience of dementia patients. Its goal is to identify the factors that limit patients' ability to join or complete a trial successfully. Clinical trial participation often favors specific demographic groups, and limited research exists on the impact of trial attributes on participation. Therefore, this study aims to analyze data from various demographic groups and identify any recurring trends that could provide valuable insights for future dementia patients.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 55 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-31
- Primary Completion
- 2025-05-31
- Completion
- 2026-05-31
More Related Trials
-
The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease
NCT01054976 ·Status: COMPLETED ·Phase: PHASE4
-
The Evaluation and Follow-up of Individuals With Memory Disorder
NCT00001480 ·Status: COMPLETED
-
A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)
NCT00874939 ·Status: TERMINATED ·Phase: PHASE1
-
Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome
NCT04149197 ·Status: TERMINATED
-
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
NCT00149175 ·Status: COMPLETED
-
Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
NCT02955706 ·Status: COMPLETED ·Phase: PHASE4
-
Deep Brain Stimulation for Treatment of Severe Alzheimer's Disease
NCT03115814 ·Status: UNKNOWN
-
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
NCT00154635 ·Status: UNKNOWN ·Phase: PHASE2
-
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422 ·Status: COMPLETED
-
Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies
NCT00230997 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
NCT01921972 ·Status: COMPLETED ·Phase: PHASE4
-
Characteristics of Treatment Responders to Galantamine
NCT01029132 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients
NCT00200538 ·Status: COMPLETED ·Phase: PHASE2
-
SSRI's and the Rate of Progression From MCI to Dementia
NCT04901494 ·Status: WITHDRAWN
-
Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease
NCT05811442 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of ChOline ALfoscerate in Patient With Mild to Moderate Alzheimer's Disease
NCT05383183 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
NCT00253201 ·Status: COMPLETED ·Phase: PHASE3
-
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
NCT02288000 ·Status: TERMINATED ·Phase: PHASE1
-
INTERCEPTOR Project: From MCI to Dementia
NCT03834402 ·Status: COMPLETED
-
Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease
NCT03363269 ·Status: COMPLETED ·Phase: PHASE2
-
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
NCT02434666 ·Status: COMPLETED ·Phase: PHASE2
-
A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia
NCT00035191 ·Status: COMPLETED ·Phase: PHASE3
-
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
NCT03703856 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
NCT00236431 ·Status: COMPLETED ·Phase: PHASE3
-
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
NCT03636204 ·Status: COMPLETED ·Phase: PHASE1